Springer Nature
Browse

sorry, we can't preview this file

13024_2019_340_MOESM1_ESM.docx (718.53 kB)

MOESM1 of Targeting tauopathy with engineered tau-degrading intrabodies

Download (718.53 kB)
journal contribution
posted on 2019-10-23, 08:26 authored by Gilbert Gallardo, Connie Wong, Sara Ricardez, Carolyn Mann, Kent Lin, Cheryl Leyns, Hong Jiang, David Holtzman
Additional file 1: Figure S1. anti-tau intrabodies fused to ubiquitin harboring a K48 or K63 mutation are polyubiquitinated. Figure S2. P301S-tg mice display aged dependent pathological tau accumulation. Figure S3. Tau-degrading intrabodies decrease tau protein levels in P301S-tg mice. Figure S4. Expression of anti-tau intrabodies in aged P301S-tg mice analyzed by immunofluorescence and fluorescence in situ analysis.

Funding

National Institute of Neurological Disorders and Stroke

History